Xefocam 8mg, 10 tablets — Made in Germany — Free Delivery

- short-term symptomatic treatment of acute mild to moderate pain in adults.

- symptomatic treatment of pain and inflammation in osteoarthritis in adults.

- symptomatic treatment of pain and inflammation in rheumatoid arthritis in adults.

- hypersensitivity to lornoxicam or to the components of the preparation

- thrombocytopenia

- hypersensitivity (symptoms similar to asthma, rhinitis, angioedema or urticaria) to other NSAIDs, including acetylsalicylic acid

- severe form of heart failure

- gastrointestinal bleeding, cerebrovascular or other bleeding

- history of gastrointestinal bleeding or perforation associated with prior NSAID therapy

- Active recurrent gastric ulcer/bleeding or history of recurrent gastric ulcer/bleeding (two or more separate episodes of advanced ulcer or bleeding)

- severe liver failure

- severe form of renal failure (serum creatinine > 700 µmol/l);

- III trimester of pregnancy (see Section "Use during pregnancy or lactation").

active ingredient: lornoxicam;

1 tablet 4 mg or 8 mg contains 4 mg or 8 mg of lornoxicam, respectively;

Excipients: povidone magnesium stearate, croscarmellose sodium; cellulose microcrystalline lactose monohydrate, polyethylene glycol 6000; titanium dioxide (E 171) talc hypromellose.

For all patients, the appropriate dosing regimen should be based on the individual response to treatment. Side effects can be minimized by using the minimum effective dose of the preparationfor a short period of time, which is necessary to control symptoms (see section "Peculiarities of use"). 

The dose is 8-16 mg of lornoxicam per day, divided into 2-3 doses. The maximum recommended daily dose is 16 mg.

Osteoarthritis and rheumatoid arthritis

An initial dose of 12 mg lornoxicam divided into 2-3 doses is recommended.

The maintenance dose should not exceed 16 mg per day.

Xefocam® film-coated tablets should be taken with a sufficient amount of water.

Elderly patients (over 65 years of age) without impaired liver or kidney function do not require dose adjustment, but lornoxicam should be used with caution, since adverse reactions from the gastrointestinal tract are worse tolerated by this category of patients.

Children.

Lornoxicam is not recommended for use in children under 18 years of age due to insufficient data on the efficacy and safety of the preparation.